Cyclooxygenase-2 inhibitors and cardiovascular thromboembolic events.

نویسنده

  • William B White
چکیده

iate discriminant analysis did not select V5 or V6 as leads in which ST-segment shift distinguished patients with acute LMCA obstruction from patients with acute obstruction of the left anterior descending coronary artery (LAD). Therefore, we do not consider ST-segment depression in leads V5 and V6 to be a characteristic finding in “LMCA AMI patients.” The findings of our patients indicated that lead aVR ST-segment elevation is not a mirror image of ST-segment depression in leads V5 and V6. Engelen et al. (4) reported that lead aVR ST-segment elevation was observed in acute obstruction of the LAD proximal to the major septal branch but not in acute LAD obstruction distal to the major septal branch. They concluded that lead aVR ST-segment elevation associated with proximal LAD obstruction was caused by transmural ischemia of the basal part of the septum. Our findings were completely in agreement with the findings by Engelen et al. (4). Our previous study (5) clearly demonstrated that isolated diagonal branch occlusion caused ECG abnormalities in leads I and aVL, while less frequently causing changes in the precordial leads compared with those caused by acute LAD obstruction, indicating that leads I and aVL represent myocardium perfused by the diagonal branch. Acute LMCA obstruction causes ischemia in myocardium perfused by the diagonal branch. Our finding that ST-segment elevation in lead aVL was observed in high incidence in LMCA AMI patients was completely in agreement with our previous study (5). The ST-segment elevation in leads aVL and I in LMCA AMI patients was caused by ischemia in myocardium perfused by the diagonal branch associated with acute LMCA obstruction.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Relative thromboembolic risks associated with COX-2 inhibitors.

OBJECTIVE To evaluate the clinical literature on cyclooxygenase-2 (COX-2) inhibitors to determine whether a greater incidence of thromboembolic events is universal within the drug class. DATA SOURCES A MEDLINE search was conducted (1996-March 2005) for key articles in the English language assessing the efficacy or safety of these agents. STUDY SELECTION AND DATA EXTRACTION Randomized, doubl...

متن کامل

THEORETICAL EFFECTS OF COX-2 INHIBITION ON THE CARDIOVASCULAR SYSTEM Theoretical Harmful Effects of COX-2 Inhibition

are prescribed commonly for the treatment of pain and inflammation caused by various musculoskeletal disorders and dysmenorrhea. Nonselective NSAIDs’ anti-inflammatory effects appear to be caused by blocking the enzyme cyclooxygenase-2 (COX-2). In addition, nonselective NSAIDs exert both their antiplatelet and detrimental effects on the gastrointestinal mucosa by blocking COX-1.1 COX-2 inhibito...

متن کامل

Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery.

BACKGROUND Valdecoxib and its intravenous prodrug parecoxib are reported to increase thromboembolic risk after coronary artery bypass grafting. The authors conducted a randomized trial to examine their safety and analgesic efficacy in patients recovering from major noncardiac surgical procedures. METHODS The trial was randomized and double-blind, with 10 days of treatment and 30 days of follo...

متن کامل

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

BACKGROUND Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with ce...

متن کامل

An economic model of long-term use of celecoxib in patients with osteoarthritis

BACKGROUND Previous evaluations of the cost-effectiveness of the cyclooxygenase-2 selective inhibitor celecoxib (Celebrex, Pfizer Inc, USA) have produced conflicting results. The recent controversy over the cardiovascular (CV) risks of rofecoxib and other coxibs has renewed interest in the economic profile of celecoxib, the only coxib now available in the United States. The objective of our stu...

متن کامل

Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?

The use of non-steroidal anti-inflammatory drugs (NSAID) is associated with a number of gastrointestinal and other adverse effects. Introduction of selective cyclooxygenase-2 (COX-2) inhibitors at the end of the 20th century raised hopes for a substantial reduction in the rate of serious events such as upper gastrointestinal ulcers, bleeding and perforations. In 2004 and 2005, predictions of so...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of the American College of Cardiology

دوره 40 3  شماره 

صفحات  -

تاریخ انتشار 2002